drugset / Trial / NCT03722680

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

NCT03722680

Phase 2 Suspended 80 enrolled UNICANCER
RandomizedParallel-groupQuadruple-blindPrevention

Summary

It is a phase II trial, randomized, parallel, double blind, multicenter, comparing riluzole versus placebo. The trial population is composed of patients ≥18 years old that have developed stage II/III colorectal cancer and are eligible for Simplified FOLFOX4 (6-12 cycles) adjuvant chemotherapy. The primary objective is to assess the preventive efficacy of riluzole on the severity of oxaliplatin-induced peripheral neuropathy during the Simplified FOLFOX4 adjuvant chemotherapy of stage II/III colorectal cancers.

Timeline

Start
2020-10-28
Primary completion
2024-08-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule 50 mg